Letrozol Aurovitas

Letrozole, the active ingredient in Letrozol Aurovitas, is an aromatase inhibitor presented as an oral formulation for systemic use. It reduces estrogen production and is employed in the treatment of postmenopausal estrogen receptor‑positive breast cancer. By selectively blocking the aromatase enzyme, it limits peripheral conversion of androgens to estrogens, thereby slowing tumor growth in hormone‑sensitive disease.

GNH USA supplies Letrozol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozol Aurovitas is an aromatase inhibitor used in hormone‑dependent breast cancer management. - Adjuvant treatment of postmenopausal ER‑positive breast cancer: reduces risk of recurrence after surgery. - Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival. - Hormone‑responsive breast cancer in combination with other systemic therapies: enhances overall therapeutic effect.

Adverse reactions may occur with Letrozol Aurovitas and should be monitored.

Common Side Effects: - Hot flashes: transient episodes of increased warmth. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Bone fracture: increased risk due to lowered estrogen. - Severe allergic reaction: rash, swelling, difficulty breathing.

When prescribing Letrozol Aurovitas, consider the following precautions. - Assess bone health: monitor for osteoporosis and consider calcium/vitamin D supplementation. - Monitor liver function: periodic liver enzyme tests are recommended. - Evaluate cardiovascular risk: watch for signs of thromboembolic disease. - Avoid use in premenopausal women: drug is not indicated for this population. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozol Aurovitas may interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: antagonizes letrozole's effect. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce efficacy. - Tamoxifen: combined use can diminish anti‑estrogen activity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase plasma concentrations. - Selective serotonin reuptake inhibitors (e.g., paroxetine): may modestly raise letrozole levels. - Warfarin: potential increase in INR, requiring closer coagulation monitoring.